Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Roger Lijnen

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Physiology

Fibrinolysis

Living Beings

Anatomy

Adipose Tissue

Concepts & Ideas

Kinetics

Disorders

Obesity

Genes & Molecular Sequences

Amino Acid Sequence

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
155
Collen, Désiré
53
Van Hoef, Berthe
22
Nelles, Luc
17
Stassen, Jean Marie
14
Dewerchin, Mieke
11
Maquoi, Erik
9
Hoylaerts, Marc
9
Carmeliet, Peter
9
Voros, Gabor
8
Scroyen, Ilse
8
Demarsin, E
7
Alessi, Marie-Christine
7
Holvoet, Paul
7
Juhan-Vague, Irène
7
Nagai, Nobuo

Sign-in to see all Coauthors

Publications

TOP 3
Ho-Tin-Noé Benoît; Enslen Hervé; Doeuvre Loïc; Corsi Jean-Marc; Lijnen H Roger; Anglés-Cano Eduardo
Role of plasminogen activation in neuronal organization and survival.
Cleuren Audrey C A; van Hoef Berthe; Hoylaerts Marc F; van Vlijmen Bart J M; Lijnen H Roger
Short-term ethinylestradiol treatment suppresses inferior caval vein thrombosis in obese mice.
Lijnen H R; Van Hoef B; Rodriguez J A; Paramo J A
Stromelysin-2 (MMP-10) deficiency does not affect adipose tissue formation in a mouse model of nutritionally induced obesity.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Roger Lijnen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Ho-Tin-Noé Benoît; Enslen Hervé; Doeuvre Loïc; Corsi Jean-Marc; Lijnen H Roger; Anglés-Cano Eduardo
Role of plasminogen activation in neuronal organization and survival.
Molecular and cellular neurosciences 2009;42(4):288-95.
2009: Cleuren Audrey C A; van Hoef Berthe; Hoylaerts Marc F; van Vlijmen Bart J M; Lijnen H Roger
Short-term ethinylestradiol treatment suppresses inferior caval vein thrombosis in obese mice.
Thrombosis and haemostasis 2009;102(5):993-1000.
2009: Lijnen H R; Van Hoef B; Rodriguez J A; Paramo J A
Stromelysin-2 (MMP-10) deficiency does not affect adipose tissue formation in a mouse model of nutritionally induced obesity.
Biochemical and biophysical research communications 2009;389(2):378-81.
2009: Scroyen Ilse; Cosemans Leentje; Lijnen H Roger
Effect of tissue inhibitor of matrix metalloproteinases-1 on in vitro and in vivo adipocyte differentiation.
Thrombosis research 2009;124(5):578-83.
2009: Suzuki Yasuhiro; Nagai Nobuo; Yamakawa Kasumi; Kawakami Junichi; Lijnen H Roger; Umemura Kazuo
Tissue-type plasminogen activator (t-PA) induces stromelysin-1 (MMP-3) in endothelial cells through activation of lipoprotein receptor-related protein.
Blood 2009;114(15):3352-8.
2009: Pakola Steve; Cahillane Geraldine; Stassen Jean-Marie; Lijnen H Roger; Verhamme Peter
Neutralization of alpha(2)-antiplasmin by microplasmin: a randomized, double-blind, placebo-controlled, ascending-dose study in healthy male volunteers.
Clinical therapeutics 2009;31(8):1688-706.
2009: Collen D; Lijnen H R
The tissue-type plasminogen activator story.
Arteriosclerosis, thrombosis, and vascular biology 2009;29(8):1151-5.
2009: Lijnen H R; Helsen S; Hoylaerts M F
Antithrombotic effect of clopidogrel in a vena cava thrombosis model in obese mice.
Thrombosis research 2009;123(5):763-4.
2009: Scroyen Ilse; Jacobs Frank; Cosemans Leen; De Geest Bart; Lijnen H Roger
Effect of plasminogen activator inhibitor-1 on adipogenesis in vivo.
Thrombosis and haemostasis 2009;101(2):388-93.
2009: Lijnen H R
Obesity and vascular risk.
Hämostaseologie 2009;29(1):44-5.
2009: Lijnen H R; Frederix L; Van Hoef B; Dewerchin M
Deficiency of vascular endothelial growth factor-D does not affect murine adipose tissue development.
Biochemical and biophysical research communications 2009;378(2):255-8.
2009: Lijnen H R
Role of fibrinolysis in obesity and thrombosis.
Thrombosis research 2009;123 Suppl 4():S46-9.
2008: Lijnen H Roger
Effect of Vioxx on adipose tissue development in mice with genetically determined obesity.
Thrombosis and haemostasis 2008;100(5):954.
2008: Lijnen H Roger; Van Hoef Berthe; Lu Hua Rong; Gallacher David J
Rofecoxib impairs adipose tissue development in a murine model of nutritionally induced obesity.
Thrombosis and haemostasis 2008;100(2):338-42.
2008: Van Hul M; Lijnen H R
A functional role of gelatinase A in the development of nutritionally induced obesity in mice.
Journal of thrombosis and haemostasis : JTH 2008;6(7):1198-206.
2008: Hemmeryckx Bianca; van Bree Rita; Van Hoef Berthe; Vercruysse Lisbeth; Lijnen H Roger; Verhaeghe Johan
Adverse adipose phenotype and hyperinsulinemia in gravid mice deficient in placental growth factor.
Endocrinology 2008;149(5):2176-83.
2008: Lijnen H Roger
Angiogenesis and obesity.
Cardiovascular research 2008;78(2):286-93.
2008: East E; Gveric D; Baker D; Pryce G; Lijnen H R; Cuzner M L
Chronic relapsing experimental allergic encephalomyelitis (CREAE) in plasminogen activator inhibitor-1 knockout mice: the effect of fibrinolysis during neuroinflammation.
Neuropathology and applied neurobiology 2008;34(2):216-30.
2008: Christiaens Valerie; Scroyen Ilse; Lijnen H Roger
Role of proteolysis in development of murine adipose tissue.
Thrombosis and haemostasis 2008;99(2):290-4.
2008: Nagai Nobuo; Hoylaerts Marc F; Gallacher David J; Lu Hua Rong; Lijnen H Roger
Prothrombotic effect of Rofecoxib in a murine venous thrombosis model.
Thrombosis research 2008;122(5):668-73.
2008: Nagai Nobuo; Hoylaerts Marc F; Cleuren Audrey C A; Van Vlijmen Bart J M; Lijnen H Roger
Obesity promotes injury induced femoral artery thrombosis in mice.
Thrombosis research 2008;122(4):549-55.
2007: Poggi M; Paulmyer-Lacroix O; Verdier M; Peiretti F; Bastelica D; Boucraut J; Lijnen H R; Juhan-Vague I; Alessi M C
Chronic plasminogen activator inhibitor-1 (PAI-1) overexpression dampens CD25+ lymphocyte recruitment after lipopolysaccharide endotoxemia in mouse lung.
Journal of thrombosis and haemostasis : JTH 2007;5(12):2467-75.
2007: Lijnen H R; Frederix L; Scroyen I
Deficiency of plasminogen activator inhibitor-2 impairs nutritionally induced murine adipose tissue development.
Journal of thrombosis and haemostasis : JTH 2007;5(11):2259-65.
2007: Nagai Nobuo; Lijnen H Roger; Cleuren Audrey C A; Rosendaal Frits R; Van Hoef Berthe; Hoylaerts Marc F; Van Vlijmen Bart J M
Factor V Leiden mutation is associated with enhanced arterial thrombotic tendency in lean but not in obese mice.
Thrombosis and haemostasis 2007;98(4):858-63.
2007: Lijnen H R; Van Hoef B; Kemp D; Collen D
Inhibition of vascular endothelial growth factor receptor tyrosine kinases impairs adipose tissue development in mouse models of obesity.
Biochimica et biophysica acta 2007;1770(9):1369-73.
2007: Suzuki Y; Nagai N; Umemura K; Collen D; Lijnen H R
Stromelysin-1 (MMP-3) is critical for intracranial bleeding after t-PA treatment of stroke in mice.
Journal of thrombosis and haemostasis : JTH 2007;5(8):1732-9.
2007: Nagai N; Van Hoef B; Lijnen H R
Plasminogen activator inhibitor-1 contributes to the deleterious effect of obesity on the outcome of thrombotic ischemic stroke in mice.
Journal of thrombosis and haemostasis : JTH 2007;5(8):1726-31.
2007: Zaman A K M Tarikuz; Fujii Satoshi; Schneider David J; Taatjes Douglas J; Lijnen H Roger; Sobel Burton E
Deleterious effects of lack of cardiac PAI-1 after coronary occlusion in mice and their pathophysiologic determinants.
Histochemistry and cell biology 2007;128(2):135-45.
2007: Scroyen I; Christiaens V; Lijnen H R
No functional role of plasminogen activator inhibitor-1 in murine adipogenesis or adipocyte differentiation.
Journal of thrombosis and haemostasis : JTH 2007;5(1):139-45.
2007: Christiaens Valerie; Voros Gabor; Scroyen Ilse; Lijnen H Roger
On the role of placental growth factor in murine adipogenesis.
Thrombosis research 2007;120(3):399-405.
2006: Lijnen H Roger; Alessi Marie-Christine; Frederix Liesbeth; Collen Désiré; Juhan-Vague Irène
Tiplaxtinin impairs nutritionally induced obesity in mice.
Thrombosis and haemostasis 2006;96(6):731-7.
2006: Voros Gabor; Sandy John D; Collen Désiré; Lijnen H Roger
Expression of aggrecan(ases) during murine preadipocyte differentiation and adipose tissue development.
Biochimica et biophysica acta 2006;1760(12):1837-44.
2006: Rossignol Patrick; Anglès-Cano Eduardo; Lijnen Henri Roger
Plasminogen activator inhibitor-1 impairs plasminogen activation-mediated vascular smooth muscle cell apoptosis.
Thrombosis and haemostasis 2006;96(5):665-70.
2006: Christiaens Valerie; Lijnen H Roger
Role of the fibrinolytic and matrix metalloproteinase systems in development of adipose tissue.
Archives of physiology and biochemistry 2006;112(4-5):254-9.
2006: Lijnen H Roger; Christiaens Valerie; Scroyen Ilse; Voros Gabor; Tjwa Marc; Carmeliet Peter; Collen Désiré
Impaired adipose tissue development in mice with inactivation of placental growth factor function.
Diabetes 2006;55(10):2698-704.
2006: Renckens Rosemarijn; Roelofs Joris J T H; Florquin Sandrine; de Vos Alex F; Pater Jennie M; Lijnen H Roger; Carmeliet Peter; van 't Veer Cornelis; van der Poll Tom
Endogenous tissue-type plasminogen activator is protective during Escherichia coli-induced abdominal sepsis in mice.
Journal of immunology (Baltimore, Md. : 1950) 2006;177(2):1189-96.
2006: Demeulemeester Diego; Scroyen Ilse; Voros Gabor; Snoeys Jan; De Geest Bart; Collen Désiré; Lijnen H Roger
Overexpression of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) in mice does not affect adipogenesis or adipose tissue development.
Thrombosis and haemostasis 2006;95(6):1019-24.
2006: Ceresa Erik; Van de Borne Kirsten; Peeters Miet; Lijnen Henri Roger; Declerck Paul J; Gils Ann
Generation of a stable activated thrombin activable fibrinolysis inhibitor variant.
The Journal of biological chemistry 2006;281(23):15878-83.
2006: Renckens Rosemarijn; Roelofs Joris J T H; Florquin Sandrine; de Vos Alex F; Lijnen H Roger; van't Veer Cornelis; van der Poll Tom
Matrix metalloproteinase-9 deficiency impairs host defense against abdominal sepsis.
Journal of immunology (Baltimore, Md. : 1950) 2006;176(6):3735-41.
2006: Rossignol P; Luttun A; Martin-Ventura J L; Lupu F; Carmeliet P; Collen D; Anglès-Cano E; Lijnen H R
Plasminogen activation: a mediator of vascular smooth muscle cell apoptosis in atherosclerotic plaques.
Journal of thrombosis and haemostasis : JTH 2006;4(3):664-70.
2006: Janssens Stefan; Lijnen H Roger
What has been learned about the cardiovascular effects of matrix metalloproteinases from mouse models?
Cardiovascular research 2006;69(3):585-94.
2006: Semeraro Fabrizio; Voros Gabor; Collen Désiré; Lijnen H Roger
Impairment of adipose tissue development by hypoxia is not mediated by plasminogen activator inhibitor-1.
Thrombosis and haemostasis 2006;95(1):174-81.
2006: Ho-Tin-Noé Benoît; Meilhac Olivier; Rossignol Patrick; Lijnen H Roger; Anglés-Cano Eduardo
Dual effect of apolipoprotein(a) on plasmin(ogen)-induced apoptosis through modulation of cell detachment of adherent cells.
Thrombosis and haemostasis 2006;95(1):142-50.
2006: Roelofs Joris J T H; Rouschop Kasper M A; Leemans Jaklien C; Claessen Nike; de Boer Anita M; Frederiks Wilma M; Lijnen H Roger; Weening Jan J; Florquin Sandrine
Tissue-type plasminogen activator modulates inflammatory responses and renal function in ischemia reperfusion injury.
Journal of the American Society of Nephrology : JASN 2006;17(1):131-40.
2006: Arnout J; Hoylaerts M F; Lijnen H R
Haemostasis.
Handbook of experimental pharmacology 2006;(176 Pt 2):1-41.
2005: Voros Gabor; Maquoi Erik; Demeulemeester Diego; Clerx Natalie; Collen Désiré; Lijnen H Roger
Modulation of angiogenesis during adipose tissue development in murine models of obesity.
Endocrinology 2005;146(10):4545-54.
2005: East Emma; Baker David; Pryce Gareth; Lijnen H Roger; Cuzner M Louise; Gveric Djordje
A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitis.
The American journal of pathology 2005;167(2):545-54.
2005: Nagai N; Suzuki Y; Van Hoef B; Lijnen H R; Collen D
Effects of plasminogen activator inhibitor-1 on ischemic brain injury in permanent and thrombotic middle cerebral artery occlusion models in mice.
Journal of thrombosis and haemostasis : JTH 2005;3(7):1379-84.
2005: Ho-Tin-Noé Benoît; Rojas Gertrudis; Vranckx Roger; Lijnen H Roger; Anglés-Cano Eduardo
Functional hierarchy of plasminogen kringles 1 and 4 in fibrinolysis and plasmin-induced cell detachment and apoptosis.
The FEBS journal 2005;272(13):3387-400.
2005: Maris Nico A; de Vos Alex F; Bresser Paul; van der Zee Jaring S; Meijers Joost C; Lijnen H Roger; Levi Marcel; Jansen Henk M; van der Poll Tom
Activation of coagulation and inhibition of fibrinolysis in the lung after inhalation of lipopolysaccharide by healthy volunteers.
Thrombosis and haemostasis 2005;93(6):1036-40.
2005: Lijnen H R; Alessi M-C; Van Hoef B; Collen D; Juhan-Vague I
On the role of plasminogen activator inhibitor-1 in adipose tissue development and insulin resistance in mice.
Journal of thrombosis and haemostasis : JTH 2005;3(6):1174-9.
2005: Lijnen H Roger
Effect of plasminogen activator inhibitor-1 deficiency on nutritionally-induced obesity in mice.
Thrombosis and haemostasis 2005;93(5):816-9.
2005: Renckens R; Roelofs J J T H; de Waard V; Florquin S; Lijnen H R; Carmeliet P; van der Poll T
The role of plasminogen activator inhibitor type 1 in the inflammatory response to local tissue injury.
Journal of thrombosis and haemostasis : JTH 2005;3(5):1018-25.
2005: Maquoi Erik; Vörös Gabor; Carmeliet Peter; Collen Désiré; Lijnen H Roger
Role of Gas-6 in adipogenesis and nutritionally induced adipose tissue development in mice.
Arteriosclerosis, thrombosis, and vascular biology 2005;25(5):1002-7.
2005: Collen Désiré; Lijnen H Roger
Thrombolytic agents.
Thrombosis and haemostasis 2005;93(4):627-30.
2005: Demeulemeester Diego; Collen Désiré; Lijnen H Roger
Effect of matrix metalloproteinase inhibition on adipose tissue development.
Biochemical and biophysical research communications 2005;329(1):105-10.
2005: Lijnen H R
Pleiotropic functions of plasminogen activator inhibitor-1.
Journal of thrombosis and haemostasis : JTH 2005;3(1):35-45.
2004: Collen D; Lijnen H R
Tissue-type plasminogen activator: a historical perspective and personal account.
Journal of thrombosis and haemostasis : JTH 2004;2(4):541-6.
2004: Voros G; Maquoi E; Collen D; Lijnen H R
Influence of membrane-bound tumor necrosis factor (TNF)-alpha on obesity and glucose metabolism.
Journal of thrombosis and haemostasis : JTH 2004;2(3):507-13.
2004: Lehoux Stéphanie; Lemarié Catherine A; Esposito Bruno; Lijnen H Roger; Tedgui Alain
Pressure-induced matrix metalloproteinase-9 contributes to early hypertensive remodeling.
Circulation 2004;109(8):1041-7.
2004: Rossignol Patrick; Ho-Tin-Noé Benoît; Vranckx Roger; Bouton Marie-Christine; Meilhac Olivier; Lijnen H Roger; Guillin Marie-Claude; Michel Jean-Baptiste; Anglés-Cano Eduardo
Protease nexin-1 inhibits plasminogen activation-induced apoptosis of adherent cells.
The Journal of biological chemistry 2004;279(11):10346-56.
2004: Lijnen H R; Van Hoef B; Umans K; Collen D
Neointima formation and thrombosis after vascular injury in transgenic mice overexpressing plasminogen activator inhibitor-1 (PAI-1).
Journal of thrombosis and haemostasis : JTH 2004;2(1):16-22.
2003: Alessi Marie-Christine; Lijnen H Roger; Bastelica Delphine; Juhan-Vague Irene
Adipose tissue and atherothrombosis.
Pathophysiology of haemostasis and thrombosis 2003;33(5-6):290-7.
2003: Lijnen H Roger
Metalloproteinases in development and progression of vascular disease.
Pathophysiology of haemostasis and thrombosis 2003;33(5-6):275-81.
2003: Maquoi Erik; Demeulemeester Diego; Vörös Gabor; Collen Désire; Lijnen H Roger
Enhanced nutritionally induced adipose tissue development in mice with stromelysin-1 gene inactivation.
Thrombosis and haemostasis 2003;89(4):696-704.
2003: Lijnen H Roger; Demeulemeester Diego; Van Hoef Berthe; Collen Désiré; Maquoi Erik
Deficiency of tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) impairs nutritionally induced obesity in mice.
Thrombosis and haemostasis 2003;89(2):249-55.
2003: Voros Gabor; Maquoi Erik; Collen Désiré; Lijnen H Roger
Differential expression of plasminogen activator inhibitor-1, tumor necrosis factor-alpha, TNF-alpha converting enzyme and ADAMTS family members in murine fat territories.
Biochimica et biophysica acta 2003;1625(1):36-42.
2003: Lijnen H Roger; Maquoi Erik; Morange Pierre; Voros Gabor; Van Hoef Berthe; Kopp Francis; Collen Désiré; Juhan-Vague Irène; Alessi Marie-Christine
Nutritionally induced obesity is attenuated in transgenic mice overexpressing plasminogen activator inhibitor-1.
Arteriosclerosis, thrombosis, and vascular biology 2003;23(1):78-84.
2002: Hamacher Jürg; Lucas Rudolf; Lijnen H Roger; Buschke Susanne; Dunant Yves; Wendel Albrecht; Grau Georges E; Suter Peter M; Ricou Bara
Tumor necrosis factor-alpha and angiostatin are mediators of endothelial cytotoxicity in bronchoalveolar lavages of patients with acute respiratory distress syndrome.
American journal of respiratory and critical care medicine 2002;166(5):651-6.
2002: Lijnen H Roger; Maquoi Erik; Demeulemeester Diego; Van Hoef Berthe; Collen Désiré
Modulation of fibrinolytic and gelatinolytic activity during adipose tissue development in a mouse model of nutritionally induced obesity.
Thrombosis and haemostasis 2002;88(2):345-53.
2002: Luca Rudolf; Lijnen H Roger; Suffredini Anthony F; Pepper Michael S; Steinberg Kenneth P; Martin Thomas R; Pugin Jérjme
Increased angiostatin levels in bronchoalveolar lavage fluids from ARDS patients and from human volunteers after lung instillation of endotoxin.
Thrombosis and haemostasis 2002;87(6):966-71.
2002: Silence J; Collen D; Lijnen H R
Reduced atherosclerotic plaque but enhanced aneurysm formation in mice with inactivation of the tissue inhibitor of metalloproteinase-1 (TIMP-1) gene.
Circulation research 2002;90(8):897-903.
2002: Lijnen H Roger
Extracellular proteolysis in the development and progression of atherosclerosis.
Biochemical Society transactions 2002;30(2):163-7.
2002: Maquoi Erik; Munaut Carine; Colige Alain; Collen Désiré; Lijnen H Roger
Modulation of adipose tissue expression of murine matrix metalloproteinases and their tissue inhibitors with obesity.
Diabetes 2002;51(4):1093-101.
2002: Lijnen H R; Van Hoef B; Frederix L; Rio M C; Collen D
Adipocyte hypertrophy in stromelysin-3 deficient mice with nutritionally induced obesity.
Thrombosis and haemostasis 2002;87(3):530-5.
2002: Lijnen H R; Maquoi E; Hansen L B; Van Hoef B; Frederix L; Collen D
Matrix metalloproteinase inhibition impairs adipose tissue development in mice.
Arteriosclerosis, thrombosis, and vascular biology 2002;22(3):374-9.
2002: Lijnen H Roger
Matrix metalloproteinases and cellular fibrinolytic activity.
Biochemistry. Biokhimii?a 2002;67(1):92-8.
2001: Silence J; Lupu F; Collen D; Lijnen H R
Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation.
Arteriosclerosis, thrombosis, and vascular biology 2001;21(9):1440-5.
2001: Dewerchin M; Collen D; Lijnen H R
Enhanced fibrinolytic potential in mice with combined homozygous deficiency of alpha2-antiplasmin and PAI-1.
Thrombosis and haemostasis 2001;86(2):640-6.
2001: Lijnen H R
Plasmin and matrix metalloproteinases in vascular remodeling.
Thrombosis and haemostasis 2001;86(1):324-33.
2001: Lijnen H R; Maquoi E; Holvoet P; Mertens A; Lupu F; Morange P; Alessi M C; Juhan-Vague I
Adipose tissue expression of gelatinases in mouse models of obesity.
Thrombosis and haemostasis 2001;85(6):1111-6.
2001: Lijnen H R; Van Hoef B; Collen D
Inactivation of the serpin alpha(2)-antiplasmin by stromelysin-1.
Biochimica et biophysica acta 2001;1547(2):206-13.
2001: Ugwu F; Lemmens G; Collen D; Lijnen H R
Matrix metalloproteinase deficiencies do not impair cell-associated fibrinolytic activity.
Thrombosis research 2001;102(1):61-9.
2001: Lijnen H R; Bloemmen F; Vereecken A; Collen D
Enzyme-linked immunosorbent assay for the specific detection of angiostatin-like plasminogen moieties in biological samples.
Thrombosis research 2001;102(1):53-9.
2001: Lijnen H R
Gene targeting in hemostasis. Alpha2-antiplasmin.
Frontiers in bioscience : a journal and virtual library 2001;6():D239-47.
2001: Arza B; De Maeyer M; Félez J; Collen D; Lijnen H R
Critical role of glutamic acid 202 in the enzymatic activity of stromelysin-1 (MMP-3).
European journal of biochemistry / FEBS 2001;268(3):826-31.
2001: Kawasaki T; Dewerchin M; Lijnen H R; Vreys I; Vermylen J; Hoylaerts M F
Mouse carotid artery ligation induces platelet-leukocyte-dependent luminal fibrin, required for neointima development.
Circulation research 2001;88(2):159-66.
2001: Lijnen H R
Role of the fibrinolytic and matrix metalloproteinase systems in arterial neointima formation after vascular injury.
Verhandelingen - Koninklijke Academie voor Geneeskunde van België 2001;63(6):605-22.
2001: Lijnen H R
Elements of the fibrinolytic system.
Annals of the New York Academy of Sciences 2001;936():226-36.
2000: Lijnen H R; Arza B; Van Hoef B; Collen D; Declerck P J
Inactivation of plasminogen activator inhibitor-1 by specific proteolysis with stromelysin-1 (MMP-3).
The Journal of biological chemistry 2000;275(48):37645-50.
2000: Arza B; Hoylaerts M F; Félez J; Collen D; Lijnen H R
Prostromelysin-1 (proMMP-3) stimulates plasminogen activation by tissue-type plasminogen activator.
European journal of biochemistry / FEBS 2000;267(21):6378-84.
2000: Lijnen H R; Collen D
Molecular basis of thrombolytic therapy.
Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 2000;7(4):373-81.
2000: Arza B; Félez J; Fábregas P; Laroche Y; Collen D; Lijnen H R
Plasminogen binding properties of macrophage inflammatory protein (MIP)-2alpha.
Thrombosis and haemostasis 2000;84(1):71-7.
2000: Kawasaki T; Dewerchin M; Lijnen H R; Vermylen J; Hoylaerts M F
Vascular release of plasminogen activator inhibitor-1 impairs fibrinolysis during acute arterial thrombosis in mice.
Blood 2000;96(1):153-60.
2000: Lijnen H R; Lupu F; Collen D; Le Naour F; Boucheix C
CD9 gene deficiency does not affect smooth muscle cell migration and neointima formation after vascular injury in mice.
Thrombosis and haemostasis 2000;83(6):956-61.
2000: Lijnen H R; Van Hoef B; Dewerchin M; Collen D
Alpha(2)-antiplasmin gene deficiency in mice does not affect neointima formation after vascular injury.
Arteriosclerosis, thrombosis, and vascular biology 2000;20(6):1488-92.
2000: Lijnen H R; Van Hoef B; Ugwu F; Collen D; Roelants I
Specific proteolysis of human plasminogen by a 24 kDa endopeptidase from a novel Chryseobacterium Sp.
Biochemistry 2000;39(2):479-88.
1999: Lijnen H R; Van Hoef B; Vanlinthout I; Verstreken M; Rio M C; Collen D
Accelerated neointima formation after vascular injury in mice with stromelysin-3 (MMP-11) gene inactivation.
Arteriosclerosis, thrombosis, and vascular biology 1999;19(12):2863-70.
1999: Lijnen H R; Soloway P; Collen D
Tissue inhibitor of matrix metalloproteinases-1 impairs arterial neointima formation after vascular injury in mice.
Circulation research 1999;85(12):1186-91.
1999: Ugwu F; Lemmens G; Collen D; Lijnen H R
Modulation of cell-associated plasminogen activation by stromelysin-1 (MMP-3).
Thrombosis and haemostasis 1999;82(3):1127-31.
1999: Lijnen H R; Collen D
Matrix metalloproteinase system deficiencies and matrix degradation.
Thrombosis and haemostasis 1999;82(2):837-45.
1999: Jespers L; Lijnen H R; Vanwetswinkel S; Van Hoef B; Brepoels K; Collen D; De Maeyer M
Guiding a docking mode by phage display: selection of correlated mutations at the staphylokinase-plasmin interface.
Journal of molecular biology 1999;290(2):471-9.
1999: Lijnen H R; Lupu F; Moons L; Carmeliet P; Goulding D; Collen D
Temporal and topographic matrix metalloproteinase expression after vascular injury in mice.
Thrombosis and haemostasis 1999;81(5):799-807.
1999: Nagai N; De Mol M; Lijnen H R; Carmeliet P; Collen D
Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice.
Circulation 1999;99(18):2440-4.
1999: Jespers L; Vanwetswinkel S; Lijnen H R; Van Herzeele N; Van Hoef B; Demarsin E; Collen D; De Maeyer M
Structural and functional basis of plasminogen activation by staphylokinase.
Thrombosis and haemostasis 1999;81(4):479-85.
1999: Morange P E; Aubert J; Peiretti F; Lijnen H R; Vague P; Verdier M; Négrel R; Juhan-Vague I; Alessi M C
Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue.
Diabetes 1999;48(4):890-5.
1999: Lijnen H R; Okada K; Matsuo O; Collen D; Dewerchin M
Alpha2-antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding.
Blood 1999;93(7):2274-81.
1998: Lijnen H R; Van Hoef B; Lupu F; Moons L; Carmeliet P; Collen D
Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes.
Arteriosclerosis, thrombosis, and vascular biology 1998;18(7):1035-45.
1998: Lijnen H R; Silence J; Lemmens G; Frederix L; Collen D
Regulation of gelatinase activity in mice with targeted inactivation of components of the plasminogen/plasmin system.
Thrombosis and haemostasis 1998;79(6):1171-6.
1998: Ugwu F; Van Hoef B; Bini A; Collen D; Lijnen H R
Proteolytic cleavage of urokinase-type plasminogen activator by stromelysin-1 (MMP-3).
Biochemistry 1998;37(20):7231-6.
1998: Jespers L; Van Herzeele N; Lijnen H R; Van Hoef B; De Maeyer M; Collen D; Lasters I
Arginine 719 in human plasminogen mediates formation of the staphylokinase:plasmin activator complex.
Biochemistry 1998;37(18):6380-6.
1998: Lijnen H R; Ugwu F; Bini A; Collen D
Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3).
Biochemistry 1998;37(14):4699-702.
1998: Lijnen H R; Silence J; Van Hoef B; Collen D
Stromelysin-1 (MMP-3)-independent gelatinase expression and activation in mice.
Blood 1998;91(6):2045-53.
1997: Okada K; Lijnen H R; Dewerchin M; Belayew A; Matsuo O; Collen D; Bernaerts R
Characterization and targeting of the murine alpha2-antiplasmin gene.
Thrombosis and haemostasis 1997;78(3):1104-10.
1997: Lijnen H R; Lasters I; Verstreken M; Collen D; Jespers L
Screening panels of monoclonal antibodies using phage-displayed antigen.
Analytical biochemistry 1997;248(2):211-5.
1997: Lasters I; Van Herzeele N; Lijnen H R; Collen D; Jespers L
Enzymatic properties of phage-displayed fragments of human plasminogen.
European journal of biochemistry / FEBS 1997;244(3):946-52.
1997: Lijnen H R; Wagner E F; Collen D
Plasminogen-dependent and -independent proteolytic activity of murine endothelioma cells with targeted inactivation of fibrinolytic genes.
Thrombosis and haemostasis 1997;77(2):362-7.
1996: Okada K; Lijnen H R; Moreau H; Vanderschueren S; Collen D
Procoagulant properties of intravenous staphylokinase versus tissue-type plasminogen activator.
Thrombosis and haemostasis 1996;76(6):857-9.
1996: Lijnen H R; Van Hoef B; Collen D
Characterization of the murine plasminogen/urokinase-type plasminogen-activator system.
European journal of biochemistry / FEBS 1996;241(3):840-8.
1996: Lijnen H R; Carmeliet P; Bouché A; Moons L; Ploplis V A; Plow E F; Collen D
Restoration of thrombolytic potential in plasminogen-deficient mice by bolus administration of plasminogen.
Blood 1996;88(3):870-6.
1996: Collen D; Bernaerts R; Declerck P; De Cock F; Demarsin E; Jenné S; Laroche Y; Lijnen H R; Silence K; Verstreken M
Recombinant staphylokinase variants with altered immunoreactivity. I: Construction and characterization.
Circulation 1996;94(2):197-206.
1995: Lijnen H R; Wnendt S; Schneider J; Janocha E; Van Hoef B; Collen D; Steffens G J
Functional properties of a recombinant chimeric protein with combined thrombin inhibitory and plasminogen-activating potential.
European journal of biochemistry / FEBS 1995;234(1):350-7.
1995: Silence K; Hartmann M; Gührs K H; Gase A; Schlott B; Collen D; Lijnen H R
Structure-function relationships in staphylokinase as revealed by "clustered charge to alanine" mutagenesis.
The Journal of biological chemistry 1995;270(45):27192-8.
1995: Lijnen H R; Moons L; Beelen V; Carmelie P; Collen D
Biological effects of combined inactivation of plasminogen activator and plasminogen activator inhibitor-1 gene function in mice.
Thrombosis and haemostasis 1995;74(4):1126-31.
1995: Lijnen H R; Collen D
Fibrinolytic agents: mechanisms of activity and pharmacology.
Thrombosis and haemostasis 1995;74(1):387-90.
1995: Collen D; Lijnen H R
Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
Thrombosis and haemostasis 1995;74(1):167-71.
1995: Verstraete M; Lijnen H R; Collen D
Thrombolytic agents in development.
Drugs 1995;50(1):29-42.
1995: Collen D; Lijnen H R
New thrombolytic agents and strategies.
Baillière's clinical haematology 1995;8(2):425-35.
1995: Lijnen H R; Collen D
Mechanisms of physiological fibrinolysis.
Baillière's clinical haematology 1995;8(2):277-90.
1995: Lijnen H R; Stassen J M; Collen D
Differential inhibition with antifibrinolytic agents of staphylokinase and streptokinase induced clot lysis.
Thrombosis and haemostasis 1995;73(5):845-9.
1995: Rodríguez P; Fuentes P; Barro M; Alvarez J G; Muñoz E; Collen D; Lijnen H R
Structural domains of streptokinase involved in the interaction with plasminogen.
European journal of biochemistry / FEBS 1995;229(1):83-90.
1995: Lijnen H R; Van Hoef B; Collen D
Interactions of staphylokinase with human platelets.
Thrombosis and haemostasis 1995;73(3):472-7.
1995: Lijnen H R
Mechanism of action and thrombolytic potential of staphylokinase.
Verhandelingen - Koninklijke Academie voor Geneeskunde van België 1995;57(4):303-14.
1995: Collen D; Lijnen H R; Vanderschueren S
Staphylokinase: fibrinolytic properties and current experience in patients with occlusive arterial thrombosis.
Verhandelingen - Koninklijke Academie voor Geneeskunde van België 1995;57(3):183-96; discussion 196-8.
1994: Collen D; De Bono D P; Lijnen H R; Pannekoek H
Development of novel thrombolytic agents.
Journal of internal medicine 1994;236(4):433-7.
1994: Lijnen H R; Bachmann F; Collen D; Ellis V; Pannekoek H; Rijken D C; Thorsen S
Mechanisms of plasminogen activation.
Journal of internal medicine 1994;236(4):415-24.
1994: Lijnen H R; De Cock F; Collen D
Characterization of the binding of urokinase-type plasminogen activator (u-PA) to plasminogen, to plasminogen-activator inhibitor-1 and to the u-PA receptor.
European journal of biochemistry / FEBS 1994;224(2):567-74.
1994: Lijnen H R; van Hoef B; Beelen V; Collen D
Characterization of the murine plasma fibrinolytic system.
European journal of biochemistry / FEBS 1994;224(3):863-71.
1994: Lijnen H R; De Cock F; Van Hoef B; Schlott B; Collen D
Characterization of the interaction between plasminogen and staphylokinase.
European journal of biochemistry / FEBS 1994;224(1):143-9.
1994: Collen D; Lijnen H R
Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential?
Blood 1994;84(3):680-6.
1994: Collen D; Stassen J M; Yasuda T; Refino C; Paoni N; Keyt B; Roskams T; Guerrero J L; Lijnen H R; Gold H K
Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
Thrombosis and haemostasis 1994;72(1):98-104.
1994: Schlott B; Hartmann M; Gührs K H; Birch-Hirschfeld E; Gase A; Vettermann S; Collen D; Lijnen H R
Functional properties of recombinant staphylokinase variants obtained by site-specific mutagenesis of methionine-26.
Biochimica et biophysica acta 1994;1204(2):235-42.
1994: Ueshima S; Holvoet P; Lijnen H R; Nelles L; Seghers V; Collen D
Expression and characterization of clustered charge-to-alanine mutants of low M(r) single-chain urokinase-type plasminogen activator.
Thrombosis and haemostasis 1994;71(1):134-40.
1993: Van de Werf F; Lijnen H R; Collen D
Coronary thrombolysis with K1K2Pu, a chimeric tissue-type and urokinase-type plasminogen activator: a feasibility study in six patients with acute myocardial infarction.
Coronary artery disease 1993;4(10):929-33.
1993: Ueshima S; Silence K; Collen D; Lijnen H R
Molecular conversions of recombinant staphylokinase during plasminogen activation in purified systems and in human plasma.
Thrombosis and haemostasis 1993;70(3):495-9.
1993: Lijnen H R; Beelen V; Declerck P J; Collen D
Bio-immunoassay for staphylokinase in blood.
Thrombosis and haemostasis 1993;70(3):491-4.
1993: Lijnen H R; Van Hoef B; Smith R A; Collen D
Functional properties of p-anisoylated plasmin-staphylokinase complex.
Thrombosis and haemostasis 1993;70(2):326-31.
1993: Collen D; Van Hoef B; Schlott B; Hartmann M; Gührs K H; Lijnen H R
Mechanisms of activation of mammalian plasma fibrinolytic systems with streptokinase and with recombinant staphylokinase.
European journal of biochemistry / FEBS 1993;216(1):307-14.
1993: Silence K; Collen D; Lijnen H R
Regulation by alpha 2-antiplasmin and fibrin of the activation of plasminogen with recombinant staphylokinase in plasma.
Blood 1993;82(4):1175-83.
1993: Silence K; Collen D; Lijnen H R
Interaction between staphylokinase, plasmin(ogen), and alpha 2-antiplasmin. Recycling of staphylokinase after neutralization of the plasmin-staphylokinase complex by alpha 2-antiplasmin.
The Journal of biological chemistry 1993;268(13):9811-6.
1993: Collen D; Schlott B; Engelborghs Y; Van Hoef B; Hartmann M; Lijnen H R; Behnke D
On the mechanism of the activation of human plasminogen by recombinant staphylokinase.
The Journal of biological chemistry 1993;268(11):8284-9.
1993: Holvoet P; Dewerchin M; Stassen J M; Lijnen H R; Tollenaere T; Gaffney P J; Collen D
Thrombolytic profiles of clot-targeted plasminogen activators. Parameters determining potency and initial and maximal rates.
Circulation 1993;87(3):1007-16.
1993: Holvoet P; Laroche Y; Stassen J M; Lijnen H R; Van Hoef B; De Cock F; Van Houtven A; Gansemans Y; Matthyssens G; Collen D
Pharmacokinetic and thrombolytic properties of chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody fused to single-chain urokinase.
Blood 1993;81(3):696-703.
1993: Lijnen H R; Van Hoef B; Collen D
Interaction of staphylokinase with different molecular forms of plasminogen.
European journal of biochemistry / FEBS 1993;211(1-2):91-7.
1993: Lijnen H R; Collen D
Molecular interactions between tissue-type plasminogen activator and plasminogen.
Methods in enzymology 1993;223():197-206.
1992: Holvoet P; Laroche Y; Lijnen H R; Van Hoef B; Brouwers E; De Cock F; Lauwereys M; Gansemans Y; Collen D
Biochemical characterization of single-chain chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody and single-chain urokinase.
European journal of biochemistry / FEBS 1992;210(3):945-52.
1992: Lijnen H R; Collen D
Remaining perspectives of mutant and chimeric plasminogen activators.
Annals of the New York Academy of Sciences 1992;667():357-64.
1992: Collen D; Lijnen H R
Fibrin-specific fibrinolysis.
Annals of the New York Academy of Sciences 1992;667():259-71.
1992: Li X K; Lijnen H R; Nelles L; Hu M H; Collen D
Biochemical properties of recombinant mutants of nonglycosylated single chain urokinase-type plasminogen activator.
Biochimica et biophysica acta 1992;1159(1):37-43.
1992: Dewerchin M; Vandamme A M; Holvoet P; De Cock F; Lemmens G; Lijnen H R; Stassen J M; Collen D
Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
Thrombosis and haemostasis 1992;68(2):170-9.
1992: Imura Y; Stassen J M; Kurokawa T; Iwasa S; Lijnen H R; Collen D
Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons.
Blood 1992;79(9):2322-9.
1992: Lu H R; Wu Z; Pauwels P; Lijnen H R; Collen D
Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
Journal of the American College of Cardiology 1992;19(6):1350-9.
1992: Nelles L; Li X K; Vanlinthout I; De Cock F; Lijnen H R; Collen D
Biochemical, thrombolytic and pharmacokinetic properties of rt-PA P47G, K49N, a substitution variant of human tissue-type plasminogen activator.
Thrombosis and haemostasis 1992;67(4):445-52.
1992: Lijnen H R; Li X K; Nelles L; Hu M H; Collen D
Biochemical properties of recombinant single-chain urokinase-type plasminogen activator mutants with deletion of Asn2 through Phe157 and/or substitution of Cys279 with Ala.
European journal of biochemistry / FEBS 1992;205(2):701-9.
1992: Vandamme A M; Dewerchin M; Lijnen H R; Bernar H; Bulens F; Nelles L; Collen D
Characterization of a recombinant chimeric plasminogen activator composed of a fibrin fragment-D-dimer-specific humanized monoclonal antibody and a truncated single-chain urokinase.
European journal of biochemistry / FEBS 1992;205(1):139-46.
1992: Collen D; Nelles L; De Cock F; Lemmens G; Van Coetsem T; Demarsin E; Lijnen H R
K1K2Pu, a recombinant t-PA/u-PA chimera with increased thrombolytic potency, consisting of amino acids 1 to 3 and 87 to 274 of human tissue-type plasminogen activator (t-PA) and amino acids 138 to 411 of human single chain urokinase-type plasminogen activator (scu-PA). Purification in centigram quantities and conditioning for use in man.
Thrombosis research 1992;65(3):421-38.
1992: Lijnen H R; Webb P D; Van Hoef B; De Cock F; Stassen J M; Prior S D; Collen D
Biochemical and biological properties of a recombinant tissue-type plasminogen activator derived from the rat JMI-229 cell line.
Thrombosis and haemostasis 1992;67(2):239-47.
1992: Li X K; Lijnen H R; Nelles L; Van Hoef B; Stassen J M; Collen D
Biochemical and biologic properties of rt-PA del (K296-G302), a recombinant human tissue-type plasminogen activator deletion mutant resistant to plasminogen activator inhibitor-1.
Blood 1992;79(2):417-29.
1992: Lijnen H R; Van Hoef B; Matsuo O; Collen D
On the molecular interactions between plasminogen-staphylokinase, alpha 2-antiplasmin and fibrin.
Biochimica et biophysica acta 1992;1118(2):144-8.
1991: Kurokawa T; Iwasa S; Kakinuma A; Stassen J M; Lijnen H R; Collen D
Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator.
Thrombosis and haemostasis 1991;66(6):684-93.
1991: Collen D; Lijnen H R
Basic and clinical aspects of fibrinolysis and thrombolysis.
Blood 1991;78(12):3114-24.
1991: Holvoet P; Laroche Y; Lijnen H R; Van Cauwenberge R; Demarsin E; Brouwers E; Matthyssens G; Collen D
Characterization of a chimeric plasminogen activator consisting of a single-chain Fv fragment derived from a fibrin fragment D-dimer-specific antibody and a truncated single-chain urokinase.
The Journal of biological chemistry 1991;266(29):19717-24.
1991: Lijnen H R; Stassen J M; Vanlinthout I; Fukao H; Okada K; Matsuo O; Collen D
Comparative fibrinolytic properties of staphylokinase and streptokinase in animal models of venous thrombosis.
Thrombosis and haemostasis 1991;66(4):468-73.
1991: Collen D; Lu H R; Lijnen H R; Nelles L; Stassen J M
Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
Circulation 1991;84(3):1216-34.
1991: Dewerchin M; Lijnen H R; Stassen J M; De Cock F; Quertermous T; Ginsberg M H; Plow E F; Collen D
Effect of chemical conjugation of recombinant single-chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies on platelet aggregation and on plasma clot lysis in vitro and in vivo.
Blood 1991;78(4):1005-18.
1991: Lu H R; Lijnen H R; Stassen J M; Collen D
Comparative thrombolytic properties of bolus injections and continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator in a hamster pulmonary embolism model.
Blood 1991;78(1):125-31.
1991: Lijnen H R; Van Hoef B; De Cock F; Okada K; Ueshima S; Matsuo O; Collen D
On the mechanism of fibrin-specific plasminogen activation by staphylokinase.
The Journal of biological chemistry 1991;266(18):11826-32.
1991: Stassen J M; Lijnen H R; Kieckens L; Collen D
Small animal thrombosis models for the evaluation of thrombolytic agents.
Circulation 1991;83(6 Suppl):IV65-72.
1991: Declerck P J; Lijnen H R; Verstreken M; Collen D
Role of alpha 2-antiplasmin in fibrin-specific clot lysis with single-chain urokinase-type plasminogen activator in human plasma.
Thrombosis and haemostasis 1991;65(4):394-8.
1991: Lijnen H R; Collen D
Towards the development of improved thrombolytic agents.
British journal of haematology 1991;77(3):261-6.
1991: Lijnen H R; Van Hoef B; Collen D
On the reversible interaction of plasminogen activator inhibitor-1 with tissue-type plasminogen activator and with urokinase-type plasminogen activator.
The Journal of biological chemistry 1991;266(7):4041-4.
1991: Collen D; Lijnen H R; Vanlinthout I; Kieckens L; Nelles L; Stassen J M
Thrombolytic and pharmacokinetic properties of human tissue-type plasminogen activator variants, obtained by deletion and/or duplication of structural/functional domains, in a hamster pulmonary embolism model.
Thrombosis and haemostasis 1991;65(2):174-80.
1991: Lijnen H R; Collen D
New strategies in the development of thrombolytic agents.
Current studies in hematology and blood transfusion 1991;(58):69-72.
1991: Collen D; Lijnen H R
Thrombolytic therapy.
Annals of the New York Academy of Sciences 1991;614():259-69.
1990: Collen D; Dewerchin M; Rapold H J; Lijnen H R; Stassen J M
Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model.
Circulation 1990;82(5):1744-53.
1990: Sabovic M; Lijnen H R; Keber D; Collen D
Correlation between progressive adsorption of plasminogen to blood clots and their sensitivity to lysis.
Thrombosis and haemostasis 1990;64(3):450-4.
1990: Lijnen H R; Van Hoef B; De Cock F; Collen D
Effect of fibrin-like stimulators on the activation of plasminogen by tissue-type plasminogen activator (t-PA)--studies with active site mutagenized plasminogen and plasmin resistant t-PA.
Thrombosis and haemostasis 1990;64(1):61-8.
1990: Nelles L; Lijnen H R; Van Nuffelen A; Demarsin E; Collen D
Characterization of domain deletion and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA).
Thrombosis and haemostasis 1990;64(1):53-60.
1990: Collen D; Lijnen H R
Molecular mechanisms of thrombolysis: implications for therapy.
Biochemical pharmacology 1990;40(2):177-86.
1990: Collen D; Lijnen H R; Bulens F; Vandamme A M; Tulinsky A; Nelles L
Biochemical and functional characterization of human tissue-type plasminogen activator variants with mutagenized kringle domains.
The Journal of biological chemistry 1990;265(21):12184-91.
1990: Declerck P J; Lijnen H R; Verstreken M; Moreau H; Collen D
A monoclonal antibody specific for two-chain urokinase-type plasminogen activator. Application to the study of the mechanism of clot lysis with single-chain urokinase-type plasminogen activator in plasma.
Blood 1990;75(9):1794-800.
1990: Lijnen H R; Nelles L; Van Hoef B; De Cock F; Collen D
Biochemical and functional characterization of human tissue-type plasminogen activator variants obtained by deletion and/or duplication of structural/functional domains.
The Journal of biological chemistry 1990;265(10):5677-83.
1990: Lijnen H R; Van Hoef B; Nelles L; Collen D
Plasminogen activation with single-chain urokinase-type plasminogen activator (scu-PA). Studies with active site mutagenized plasminogen (Ser740----Ala) and plasmin-resistant scu-PA (Lys158----Glu).
The Journal of biological chemistry 1990;265(9):5232-6.
1990: Lijnen H R; Dewerchin M; De Cock F; Collen D
Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator.
Thrombosis research 1990;57(3):333-42.
1990: Lijnen H R; Van Hoef B; Collen D
On the molecular interactions between fibrin, tissue-type plasminogen activator and plasminogen.
Thrombosis research. Supplement 1990;10():45-54.
1989: Sabovic M; Lijnen H R; Keber D; Collen D
Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators.
Thrombosis and haemostasis 1989;62(4):1083-7.
1989: Dewerchin M; Lijnen H R; Van Hoef B; De Cock F; Collen D
Biochemical properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin.
European journal of biochemistry / FEBS 1989;185(1):141-9.
1989: Lijnen H R; Van Hoef B; De Cock F; Collen D
The mechanism of plasminogen activation and fibrin dissolution by single chain urokinase-type plasminogen activator in a plasma milieu in vitro.
Blood 1989;73(7):1864-72.
1989: Lijnen H R; Collen D
Interaction of heparin with histidine-rich glycoprotein.
Annals of the New York Academy of Sciences 1989;556():181-5.
1988: Lijnen H R; Piérard L; Reff M E; Gheysen D
Characterization of a chimaeric plasminogen activator obtained by insertion of the second kringle structure of tissue-type plasminogen activator (amino acids 173 through 262) between residues Asp130 and Ser139 of urokinase-type plasminogen activator.
Thrombosis research 1988;52(5):431-41.
1988: Lijnen H R; Nelles L; Van Hoef B; Demarsin E; Collen D
Characterization of a chimeric plasminogen activator consisting of amino acids 1 to 274 of tissue-type plasminogen activator and amino acids 138 to 411 of single-chain urokinase-type plasminogen activator.
The Journal of biological chemistry 1988;263(35):19083-91.
1988: Lijnen H R; Nelles L; Van Hoef B; Demarsin E; Collen D
Structural and functional characterization of mutants of recombinant single-chain urokinase-type plasminogen activator obtained by site-specific mutagenesis of Lys158, Ile159 and Ile160.
European journal of biochemistry / FEBS 1988;177(3):575-82.
1988: Lijnen H R; Nelles L; Van Hoef B; De Cock F; Collen D
Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.
Thrombosis and haemostasis 1988;60(2):247-50.
1988: Lijnen H R; Collen D
New strategies in the development of thrombolytic agents.
Blut 1988;57(4):147-62.
1988: Lijnen H R; Nelles L; Holmes W E; Collen D
Biochemical and thrombolytic properties of a low molecular weight form (comprising Leu144 through Leu411) of recombinant single-chain urokinase-type plasminogen activator.
The Journal of biological chemistry 1988;263(12):5594-8.
1988: Lijnen H R; Van Hoef B; Nelles L; Holmes W E; Collen D
Enzymatic properties of single-chain and two-chain forms of a Lys158----Glu158 mutant of urokinase-type plasminogen activator.
European journal of biochemistry / FEBS 1988;172(1):185-8.
1988: Lijnen H R; Collen D
Mechanisms of plasminogen activation by mammalian plasminogen activators.
Enzyme 1988;40(2-3):90-6.
1987: Lijnen H R; Van Hoef B; Collen D
Activation with plasmin of tow-chain urokinase-type plasminogen activator derived from single-chain urokinase-type plasminogen activator by treatment with thrombin.
European journal of biochemistry / FEBS 1987;169(2):359-64.
1987: Holmes W E; Lijnen H R; Nelles L; Kluft C; Nieuwenhuis H K; Rijken D C; Collen D
Alpha 2-antiplasmin Enschede: alanine insertion and abolition of plasmin inhibitory activity.
Science (New York, N.Y.) 1987;238(4824):209-11.
1987: Gheysen D; Lijnen H R; Piérard L; de Foresta F; Demarsin E; Jacobs P; De Wilde M; Bollen A; Collen D
Characterization of a recombinant fusion protein of the finger domain of tissue-type plasminogen activator with a truncated single chain urokinase-type plasminogen activator.
The Journal of biological chemistry 1987;262(24):11779-84.
1987: Nelles L; Lijnen H R; Collen D; Holmes W E
Characterization of a fusion protein consisting of amino acids 1 to 263 of tissue-type plasminogen activator and amino acids 144 to 411 of urokinase-type plasminogen activator.
The Journal of biological chemistry 1987;262(22):10855-62.
1987: Holmes W E; Lijnen H R; Collen D
Characterization of recombinant human alpha 2-antiplasmin and of mutants obtained by site-directed mutagenesis of the reactive site.
Biochemistry 1987;26(16):5133-40.
1987: Lijnen H R; Holmes W E; van Hoef B; Wiman B; Rodriguez H; Collen D
Amino-acid sequence of human alpha 2-antiplasmin.
European journal of biochemistry / FEBS 1987;166(3):565-74.
1987: Nelles L; Lijnen H R; Collen D; Holmes W E
Characterization of recombinant human single chain urokinase-type plasminogen activator mutants produced by site-specific mutagenesis of lysine 158.
The Journal of biological chemistry 1987;262(12):5682-9.
1987: Holmes W E; Nelles L; Lijnen H R; Collen D
Primary structure of human alpha 2-antiplasmin, a serine protease inhibitor (serpin).
The Journal of biological chemistry 1987;262(4):1659-64.
1986: Collen D; De Cock F; Demarsin E; Lijnen H R; Stump D C
Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
Thrombosis and haemostasis 1986;56(1):35-9.

Sign-in to see more